FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)  

Oncologic Drugs Advisory Committee (ODAC) Meeting  
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
April 12, 2016  

FINAL MEETING ROSTER  

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)  

LCDR Jennifer A. Shepherd, RPh  
Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA  
Silver Spring, Maryland  

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)  

Deborah K. Armstrong, MD  
(Chairperson)  
Professor of Oncology  
The Sidney Kimmel Comprehensive Cancer Center  
at Johns Hopkins  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland  

Bernard F. Cole, PhD  
Professor  
Department of Mathematics and Statistics  
University of Vermont  
Burlington, Vermont  

Tito Fojo, MD, PhD  
Professor of Medicine  
Division of Medical Oncology  
Department of Medicine  
Columbia University  
New York, New York  

Michael E. Menefee, MD  
Assistant Professor of Medicine  
Mayo Clinic Jacksonville  
Jacksonville, Florida  

Grzegorz S. Nowakowski, MD  
Assistant Professor of Medicine  
Mayo Clinic Rochester  
Rochester, Minnesota  

Brian I. Rini, MD, FACP  
Professor of Medicine  
Cleveland Clinic Taussig Cancer Institute  
Glickman Urological and Kidney Institute  
Cleveland, Ohio  

Bruce J. Roth, MD  
Professor of Medicine  
Division of Oncology  
Washington University School of Medicine  
St. Louis, Missouri
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP
Executive Medical Director, Amgen Oncology
Therapeutic Area Head, US Medical Organization
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

William Douglas Figg, Sr., PharmD, MBA
Senior Investigator and Head of the Clinical
Pharmacology Program in the Office of the Clinical
Director, Center for Cancer Research (CCR)
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Head of Molecular Pharmacology Section
Deputy Branch Chief in the Genitourinary
Malignancies Branch, CCR, NCI, NIH
Bethesda, Maryland

Terry Gillespie
(Patient Representative)
Westmont, Illinois

Donald E. Mager, PharmD, PhD
Associate Professor of Pharmaceutical Sciences
Department of Pharmaceutical Sciences
University at Buffalo, State University of New York
Buffalo, New York

Michele Orza, ScD
(Acting Consumer Representative)
Senior Advisor to the Executive Director
Patient-Centered Outcomes Research Institute
(PCORI)
Washington, District of Columbia

Arun Rajan, MD
Associate Research Physician
Thoracic and GI Oncology Branch
CCR, NCI, NIH
Bethesda, Maryland

Eva Szabo, MD
Chief
Lung & Upper Aerodigestive Cancer Research Group
Division of Cancer Prevention, NCI, NIH
Bethesda, Maryland
FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)  

Oncologic Drugs Advisory Committee (ODAC) Meeting  
April 12, 2016  

FINAL MEETING ROSTER (cont.)

<table>
<thead>
<tr>
<th>FDA PARTICIPANTS (Non-Voting)</th>
</tr>
</thead>
</table>
| **Richard Pazdur, MD**  
Director  
Office of Hematology and Oncology Products (OHOP)  
Office of New Drugs (OND), CDER, FDA |
| **Patricia Keegan, MD**  
Director  
Division of Oncology Products 2 (DOP2)  
OHOP, OND, CDER, FDA |
| **Gideon Blumenthal, MD**  
Medical Team Leader  
Thoracic/Head & Neck Cancer Team  
DOP2, OHOP, OND, CDER, FDA |
| **'Lola Fashoyin-Aje, MD, MPH**  
Medical Officer  
Thoracic/Head & Neck Cancer Team  
DOP2, OHOP, OND, CDER, FDA |
| **Chao Liu, PhD**  
Pharmacometrics Reviewer  
Division of Pharmacometrics (DPM)  
Office of Clinical Pharmacology (OCP)  
Office of Translational Sciences (OTS)  
CDER, FDA |